Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarity AD: Lecanemab in Early Alzheimer's Disease
NCT03887455Phase 3Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of lecanemab in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd.. Started Mar 2019; status: active, not recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03887455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887455.